Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma
This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin’s lymphoma (HL) are presented. The clinical application of IIBI increases the efficacy of treatment. I...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
International Medical Research and Development Corporation
2015-12-01
|
| Series: | International Journal of Biomedicine |
| Subjects: | |
| Online Access: | http://ijbm.org/articles/Article5(4)_OA9.pdf |
| _version_ | 1818609254496468992 |
|---|---|
| author | Daniar R. Aspetov Maria N. Omarova Lyazzat Zh. Orakbay Raiymkul K. Karakulov Kairat S. Doskhozhayev Bayan Kh. Zhumatova Meruyert D. Chazhayeva |
| author_facet | Daniar R. Aspetov Maria N. Omarova Lyazzat Zh. Orakbay Raiymkul K. Karakulov Kairat S. Doskhozhayev Bayan Kh. Zhumatova Meruyert D. Chazhayeva |
| author_sort | Daniar R. Aspetov |
| collection | DOAJ |
| description | This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin’s lymphoma (HL) are presented. The clinical application of IIBI increases the efficacy of treatment. IIBI in combination with CRT induces the production of highly active endogenous IFN-α/β, provides a marked regression of the affected lymph nodes in a short period (within 7 to 10 days) of treatment, relieves B symptoms, and increases by 2 times the length of remission in patients with refractory HL. |
| first_indexed | 2024-12-16T14:55:37Z |
| format | Article |
| id | doaj.art-6495192baa734409ba7ff5d49832bcd6 |
| institution | Directory Open Access Journal |
| issn | 2158-0510 2158-0529 |
| language | English |
| last_indexed | 2024-12-16T14:55:37Z |
| publishDate | 2015-12-01 |
| publisher | International Medical Research and Development Corporation |
| record_format | Article |
| series | International Journal of Biomedicine |
| spelling | doaj.art-6495192baa734409ba7ff5d49832bcd62022-12-21T22:27:28ZengInternational Medical Research and Development CorporationInternational Journal of Biomedicine2158-05102158-05292015-12-0154214218Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s LymphomaDaniar R. Aspetov0Maria N. Omarova1Lyazzat Zh. Orakbay2Raiymkul K. Karakulov3Kairat S. Doskhozhayev4Bayan Kh. Zhumatova5Meruyert D. Chazhayeva6Scientific Centre of Hygiene and Epidemiology; Almaty, KazakhstanScientific Centre of Hygiene and Epidemiology; Almaty, KazakhstanScientific Centre of Hygiene and Epidemiology; Almaty, KazakhstanKazakh Research Institute of Oncology and Radiology; Almaty, KazakhstanKazakh Research Institute of Oncology and Radiology; Almaty, KazakhstanScientific Centre of Hygiene and Epidemiology; Almaty, KazakhstanScientific Centre of Hygiene and Epidemiology; Almaty, KazakhstanThis study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin’s lymphoma (HL) are presented. The clinical application of IIBI increases the efficacy of treatment. IIBI in combination with CRT induces the production of highly active endogenous IFN-α/β, provides a marked regression of the affected lymph nodes in a short period (within 7 to 10 days) of treatment, relieves B symptoms, and increases by 2 times the length of remission in patients with refractory HL.http://ijbm.org/articles/Article5(4)_OA9.pdfHodgkin’s lymphoma;chemoradiotherapy;immunotherapy;INF inducer; |
| spellingShingle | Daniar R. Aspetov Maria N. Omarova Lyazzat Zh. Orakbay Raiymkul K. Karakulov Kairat S. Doskhozhayev Bayan Kh. Zhumatova Meruyert D. Chazhayeva Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma International Journal of Biomedicine Hodgkin’s lymphoma; chemoradiotherapy; immunotherapy; INF inducer; |
| title | Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma |
| title_full | Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma |
| title_fullStr | Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma |
| title_full_unstemmed | Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma |
| title_short | Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma |
| title_sort | clinical use of the interferon inducer iibi in patients with refractory hodgkin s lymphoma |
| topic | Hodgkin’s lymphoma; chemoradiotherapy; immunotherapy; INF inducer; |
| url | http://ijbm.org/articles/Article5(4)_OA9.pdf |
| work_keys_str_mv | AT daniarraspetov clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma AT marianomarova clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma AT lyazzatzhorakbay clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma AT raiymkulkkarakulov clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma AT kairatsdoskhozhayev clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma AT bayankhzhumatova clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma AT meruyertdchazhayeva clinicaluseoftheinterferoninduceriibiinpatientswithrefractoryhodgkinslymphoma |